RFG
TRVI icon

REAP Financial Group’s Trevi Therapeutics TRVI Stock Holding History

REAP Financial Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,000
Closed -$18.3K – 595
2025
Q3 		$18.3K Buy
+2,000
New +$15K ﹤0.01% 353

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

REAP Financial Group's TRVI Position: Q4 2025 in Review

REAP Financial Group sold out of Trevi Therapeutics (TRVI) in Q4 2025, closing a stake of 2,000 shares — an estimated $18.3K sold.

REAP Financial Group first reported a position in TRVI in Q3 2025 and held it in 1 quarter. The position peaked at $18.3K in Q3 2025. 184 funds tracked by Wall St. Rank hold TRVI as of Q4 2025.

  • REAP Financial Group reported no remaining Trevi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • REAP Financial Group sold 2,000 Trevi Therapeutics shares in Q4 2025, an estimated $18.3K.
  • REAP Financial Group first reported a position in Trevi Therapeutics in Q3 2025 and held it in 1 quarter.
  • REAP Financial Group's Trevi Therapeutics position peaked at $18.3K in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2025.

Based on REAP Financial Group's 13F filing for Q4 2025, filed 10 Feb 2026.